Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dual antiplatelet therapy duration after successful PCI for chronic coronary occlusion
2023-508148-23-01Phase 3Authorised
- Sponsor
- Assistance Publique-Hôpitaux de Marseille
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of lysine acetylsalicylate and clopidogrel in Chronic total occlusion of the coronary artery (CTO) (2 arms), sponsored by Assistance Publique-Hôpitaux de Marseille. Primary endpoint: Net adverse clinical events. Planned start Dec 2024; status: authorised.
02
Drugs
lysine acetylsalicylateclopidogrel
03
Conditions
Chronic total occlusion of the coronary artery (CTO)
Beyond the preview
Go deeper on 2023-508148-23-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508148-23-01.